



**EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 15<sup>TH</sup> JANUARY 2020  
AT 12.30pm**

**IN SEMINAR ROOM 3, LEARNING & DEVELOPMENT CENTRE,  
ROYAL BLACKBURN HOSPITAL**

**PRESENT:**

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chair)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL

**IN ATTENDANCE:**

Ms L Prince	Medicines Management Technician EL CCG
Elizabeth White	Tissue Viability Lead Nurse ELHT
Kirsty Holt	Infection Prevention & Control Matron ELHT

**2020/001: APOLOGIES:**

Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

**2020/002: DECLARATION OF INTEREST**

None declared – relevant to agenda items.

**2020/003: MINUTES OF DECEMBER MEETING:**

Item 2019/174 should state November meeting not October  
Item 2019/178 Guideline for Antihyperglycaemic Therapy should state SJ not SR  
Otherwise accepted as a correct record.

**2020/004: MATTERS ARISING:**

**Not on action sheet**

**2019/179 Formulary updates – Slophyllin®** – a hot topic will be sent out with pathway for management of current patients.

#### **From action sheet**

**2019/131: Treatment of Vitamin B12 Deficiency Draft** – A pathway is currently being developed with Jane Oakey from Path Lab. To be brought to ELMMB when completed.

**2019/143: LMMG Recommendations (From Sept LMMG) - ADHD Shared Care Guideline – updated** - paediatric pharmacist due to raise concerns over lack of compliance with shared care guideline at community paediatric directorate meeting (being held today). A suggestion was made that they have a standard letter to send to GPs. Will feed back outcomes of discussion to ELMMB

**2019/163: LSCMMG Recommendations (from Oct LSCMMG) Liothyronine New Medicine recommendation** – endocrinologists have agreed the line ‘the treatment of thyrotoxicosis as an adjunct to carbimazole to prevent sub-clinical hypothyroidism developing during treatment’ can be removed.

**2019/176: New Product Request – Rifaxamin for Small Intestinal Bacterial Overgrowth** – referred to LSCMMG for review and has been added to the work plan. Defer presentation & discussion at ELMMB until LSCMMG review is available.

**2019/178: LSCMMG Recommendations (From Nov LSCMMG) - Rheumatoid Arthritis High Cost drugs Pathway – updated** – will be ready for February meeting.

#### **2020/005: NEW PRODUCT REQUEST – OCTENILLIN WOUND IRRIGATION SOLUTION AND GEL**

Elizabeth White and Kirsty Holt in attendance for this item.

Requested by Infection Control team and Tissue Viability Lead for use cleansing complex wounds, when there is a suspicion of MRSA, before dressings are applied. Octenillin does not require a contact time whereas the current product used require a 15 minute contact time with the wound before cleansing and application of dressings. It is hoped to provide more optimal wound care to complex wounds, reduce oral antimicrobial requirements, length of hospital stay and reduce district nurse time in the community. It was agreed that the octenillin wound irrigation solution and gel could replace prontosan on the wound care formulary for use following specialist advice. There will be a leaflet produced to support appropriate use.

**Resolved: Octenillin wound irrigation solution and gel added to wound care formulary to replace prontosan.**

#### **2020/006: LSCMMG CONSULTATIONS (for Feb LSCMMG)**

**Octreotide /Lanreotide for orthostatic intolerance disorders New Medicine Assessment** – evidence is poor for this unlicensed indication, recommend black.

**Nortriptyline for chronic neuropathic pain New Medicines Assessment** – discussed similar effects to amitriptyline but maybe better tolerated, not included in NICE guidance, more expensive than other agents in current pathway. ELMMB recommend black.

**Resolved: Comments to be sent to LSCMMG**

## **2020/007: LSCMMG Recommendations (From Dec LSCMMG)**

**Cannabis-based Medicinal Products for the management of patients with Chronic Pain – updated** - accepted as written for ELHE.

**Guidelines for the prescribing of Nutritional Supplements Post Bariatric Surgery - updated** – information on private patients amended. Discussed the different traffic lights for different indications is in line with self-care policy. Accepted as written for ELHE.

## **2020/008: FORMULARY UPDATES**

**Trimovate ® cream** – this cream is now available again and is considered an essential and unique preparation for managing skin conditions with fungal and bacterial infection. It was agreed to include back on formulary. **Traffic Light: GREEN**

**Slozem®** – discontinued by manufacturer, replace on formulary with Zemtard XL® brand of diltiazem for first line use with the Viazem XL® brand an option.

**Resolved: Formulary to be updated as above**

## **2020/009: NICE RECOMMENDATIONS (from Dec)**

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome [TA614] is recommended as an option by NICE. Approved in line with NICE. NHS England Commissioned **Traffic Light: RED**

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615) is recommended as an option by NICE. Approved in line with NICE. NHS England Commissioned **Traffic Light: RED**

Cladribine for treating relapsing–remitting multiple sclerosis (TA616) is recommended as an option by NICE. Approved in line with NICE. NHS England Commissioned **Traffic Light: RED**

## **STANDING ITEMS**

**2020/010: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES - December 2019**  
Minutes acknowledged

### **Any Other Business**

The Joint Committee of CCG's will be considering some of the recommendations from LSCMMG for a commissioning decision. The decision will then be brought to ELMMB for information.

LR will update the managed introduction of new drugs policy to reflect this change.

Transplant medication interactions – an incident has highlighted that prescribers should be alert to possible interactions that may occur when other medications are prescribed for patients taking transplant medications. A Hot Topic to be produced.

SJ described a recent study, Hygia chronotherapy trial, in the European Heart Journal that has highlighted that taking hypertension treatment at bedtime, rather than other times of day, reduces major cardiovascular events. To be discussed with cardiology.

**DATE OF NEXT MEETING – Wednesday 19<sup>th</sup> February 2020 12.30pm**, Seminar Room 6, Learning & Development centre, RBH

**2020 Meetings** – All on 3<sup>rd</sup> Wednesday of the month at 12.30pm – 2pm

January 15<sup>th</sup>  
February 19<sup>th</sup>  
March 18<sup>th</sup>  
April 15<sup>th</sup>  
May 20<sup>th</sup>  
June 17<sup>th</sup>  
July 15<sup>th</sup>  
August 19<sup>th</sup>  
September 16<sup>th</sup>  
October 21<sup>st</sup>  
November 18<sup>th</sup>  
December 16<sup>th</sup>

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 15<sup>TH</sup> JANUARY 2020**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2019/131</b>	<b>Treatment Of Vitamin B12 Deficiency Draft</b> – pathway to be developed	LR/JV	Feb 20
<b>2019/143</b>	<b>ADHD Shared Care Guideline</b> Follow up the compliance with shared care with paediatric pharmacist	VG	Nov 19
<b>2019/178</b>	<b>LSCMMG Recommendations (From Nov LSCMMG) - Rheumatoid Arthritis High Cost drugs Pathway – updated</b> - Add biosimilar brand names and send to rheumatologists for comments	LR / JV	Feb 20